Arno Therapeutics Announces Poster Presentation At ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity Of AR-42
Written on December 16, 2009 – 9:32 am | by admin
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs). AR-42 is a broad spectrum inhibitor of both histone and non-histone deacetylation proteins that demonstrated potent activity against Acute Myeloid Leukemia (AML) stem cells. Continue training!
Tags: Annual, Arno Therapeutics